Complete antiaging treatment plan combining drugs and topicals.
A complete anti-ageing plan has two parts: medicines for the ageing that shortens life — blood pressure, cholesterol, blood sugar, hormones where needed — and topicals and procedures for the ageing that shows — sunscreen, tretinoin, pigmentation treatment, Botox-type injections or fillers if wanted. Different doctors build each part, and one set of measurements, one review schedule and one pharmacist's check of everything you take hold them together. Off-label longevity drugs, peptides and IV drips are not part of a complete plan; they are what makes a plan incomplete.
A complete anti-ageing treatment plan has two halves that are built by different clinicians on different evidence and joined by one baseline and one review schedule. Ranked by what each component carries: the systemic half first — antihypertensives to target, ApoB-lowering therapy, a GLP-1 agonist where indicated, hormone therapy for symptoms in the window — because these are the drugs with randomised evidence for the ageing that shortens life; the topical half second — daily sunscreen, tretinoin, a depigmenting course where needed — because these have randomised evidence for the ageing that shows; procedures third — neuromodulators, fillers, devices — for what topicals cannot reach; the baseline and monitoring fourth, because without them neither half is a plan; and the medication review fifth, because the two halves interact and the systemic half interacts with everything else the patient takes. What does not belong in a complete plan: off-label longevity drugs as a first line, compounded peptides, IV therapy, and any item added because it was on a menu. Complete means both halves covered with evidence, not every product available.
- The systemic half changes how long you live and the topical half changes how old you look; a plan is complete only when both are built on evidence for exactly those outcomes.
- The systemic half is internal medicine — blood pressure, ApoB, glucose, hormones — and its drugs are generic, boring and the most effective anti-ageing pharmaceuticals ever tested.
- The topical half is dermatology — sunscreen, tretinoin, pigmentation agents, procedures — and its evidence is on appearance, which is the only thing it claims.
- One baseline and one monitoring schedule join the halves; one medication review keeps them from colliding.
- A complete plan is short. The items that make it long are the ones with the least evidence.
The components, ranked by what each carries
Ranked on: how much of the plan's outcome — lifespan and healthspan on one side, appearance on the other — each component carries on randomised evidence, and how much the plan fails without it. The order is also the build order.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | The systemic half: blood pressure, ApoB, glucose, hormones — treated to target | Changes how long you live; the drugs with mortality evidence | GRADE AEstablished |
| 2 | The topical half: sunscreen, tretinoin, a depigmenting course where needed | Changes how old you look; the topicals with appearance evidence | GRADE AEstablished |
| 3 | Procedures for what topicals cannot reach | Dynamic lines, volume, laxity — on a schedule | GRADE BPromising |
| 4 | The baseline and the monitoring schedule | What joins the halves and makes them a plan | GRADE AEstablished |
| 5 | The medication and supplement review | Keeps the halves from colliding with each other and with everything else | GRADE AEstablished |
| 6 | Lifestyle prescriptions written into the plan | Carry more than any drug; belong on the same page | GRADE AEstablished |
| 7 | Off-label longevity drugs — rapamycin, metformin in non-diabetics, senolytics, hormone 'optimisation' | Not part of a complete plan; at most an appendix with consent | GRADE CEarly |
| 8 | Compounded peptides, IV therapy, exosomes, stem cells, 'medical-grade' cosmeceuticals as core items | What makes a plan incomplete | GRADE DInsufficient or unsafe |
- 01
The systemic half: blood pressure, ApoB, glucose, hormones — treated to target
GRADE AEstablishedChanges how long you live; the drugs with mortality evidenceAntihypertensives to target (fewer events and deaths in trials); ApoB-lowering therapy where elevated (lower all-cause mortality across 26 trials); a GLP-1 agonist where obesity with cardiovascular disease or diabetes indicates it (fewer events in SELECT); menopausal hormone therapy for symptoms within the window; testosterone only for diagnosed hypogonadism. Built by internal medicine on measured findings. This half carries the lifespan.
- 02
The topical half: sunscreen, tretinoin, a depigmenting course where needed
GRADE AEstablishedChanges how old you look; the topicals with appearance evidenceDaily broad-spectrum sunscreen (the only intervention proven to slow skin ageing); tretinoin introduced slowly and kept (reversal of texture, fine wrinkles and pigmentation with new collagen on biopsy); hydroquinone or the triple combination in courses, tranexamic acid or azelaic acid, where pigmentation is a concern. Built by dermatology. This half carries the appearance.
- 03
Procedures for what topicals cannot reach
GRADE BPromisingDynamic lines, volume, laxity — on a scheduleBotulinum toxin for expression lines, hyaluronic-acid or biostimulatory fillers for volume, lasers or energy devices for laxity and deep texture, each with controlled evidence for its outcome and each dependent on the operator. Added once the topical half is stable; scheduled rather than bundled.
- 04
The baseline and the monitoring schedule
GRADE AEstablishedWhat joins the halves and makes them a planOne baseline: blood pressure; ApoB and lipoprotein(a); HbA1c with fasting glucose and insulin; kidney, liver and thyroid function; ferritin and vitamin D; sex hormones where symptomatic; a skin examination with photographs; a skin-cancer check. One schedule: lipids at three months, blood pressure at home, HbA1c at three to six months, photographs at three and six months, procedure effects separated in the photographs, an annual skin check. Without it, neither half can be shown to work.
- 05
The medication and supplement review
GRADE AEstablishedKeeps the halves from colliding with each other and with everything elseThe systemic half interacts with existing medicines; the topical half stacks irritants if not sequenced; the supplements most people already take interact with both. A pharmacist's review at baseline and at each change is the component most often missing from 'complete' plans, and the cheapest.
- 06
Lifestyle prescriptions written into the plan
GRADE AEstablishedCarry more than any drug; belong on the same pageNot smoking (the largest single lever on both halves), resistance and aerobic training, sleep, protein, alcohol. A complete plan writes them down with the same specificity as the prescriptions, because they have more evidence than most of the prescriptions and they determine whether the drugs are needed at all.
- 07
Off-label longevity drugs — rapamycin, metformin in non-diabetics, senolytics, hormone 'optimisation'
GRADE CEarlyNot part of a complete plan; at most an appendix with consentNo human evidence for an ageing outcome; known adverse-effect profiles; interactions with the systemic half. A complete plan either omits them or appends them as explicit experiments with informed consent, baseline, monitoring and a stopping rule — after both halves are built, never in place of either.
- 08
Compounded peptides, IV therapy, exosomes, stem cells, 'medical-grade' cosmeceuticals as core items
GRADE DInsufficient or unsafeWhat makes a plan incompleteNo trial evidence for the claims, and for several no lawful route. Their presence in a plan displaces the items with evidence and marks the plan as a menu.
The complete plan on one page
Two halves, one baseline, one schedule
| Half | Built by | Components | Evidence for | Monitored by |
|---|---|---|---|---|
| Systemic | Internal medicine / GP | Antihypertensive to target; ApoB-lowering therapy; GLP-1 agonist where indicated; HRT for symptoms in window; testosterone for diagnosed deficiency | Fewer events, lower mortality; symptoms and bone | Blood pressure at home; lipids at 3 months; HbA1c 3–6 months; hormone levels where relevant |
| Topical | Dermatology | Daily sunscreen; tretinoin, introduced slowly; depigmenting course where needed; supporting moisturiser and cleanser | Less future photoageing; reversal of texture, wrinkles, pigmentation | Photographs at 0, 3, 6 months; annual skin check |
| Procedures | Dermatology / trained injector | Botulinum toxin; fillers or biostimulators; devices — as warranted, scheduled | Dynamic lines; volume; laxity | Photographs separating each effect |
| Joint | Pharmacist + both clinicians | Baseline panel; medication and supplement review; lifestyle prescriptions; review schedule with triggers | — | Annual full review; triggers: new symptom, new drug, abnormal result |
| Appendix (optional) | A clinician willing to consent you | Off-label longevity drugs as explicit n-of-1 experiments with a stopping rule | None for ageing | Baseline, follow-up, stop date |
Frequently asked questions
What does a complete anti-ageing treatment plan combining drugs and topicals look like?
Two halves built by different clinicians: a systemic half — antihypertensives to target, ApoB-lowering therapy, a GLP-1 agonist where indicated, hormone therapy for symptoms in the window — with evidence for the ageing that shortens life; and a topical half — daily sunscreen, tretinoin, a depigmenting course where needed, procedures for lines and volume — with evidence for the ageing that shows. One baseline, one monitoring schedule, one medication review and written lifestyle prescriptions join them. Off-label longevity drugs, peptides and IV therapy are not part of it.
Who should build a complete anti-ageing plan?
Two clinicians and a pharmacist: an internal-medicine physician or GP for the systemic half, a dermatologist for the topical half and procedures, and a pharmacist for the medication and supplement review that keeps the halves from colliding. A single 'longevity protocol' from one prescriber usually has weaker evidence and weaker monitoring for each half.
Which drugs matter most in a complete plan?
The systemic ones with mortality evidence: antihypertensives to target and ApoB-lowering therapy where elevated, then a GLP-1 agonist where obesity with cardiovascular disease or diabetes indicates it. They are generic, unglamorous and the most effective anti-ageing pharmaceuticals ever tested. The topical half changes appearance; the systemic half changes lifespan.
Do rapamycin, metformin or peptides belong in a complete plan?
Not as components. Off-label longevity drugs have no human evidence for an ageing outcome and known adverse effects; at most they are an optional appendix — explicit experiments with informed consent, baseline, monitoring and a stopping rule — after both halves are built. Compounded peptides, IV therapy and exosomes have no place at all; their presence marks a plan as a menu.
How are the two halves monitored?
The systemic half by blood pressure at home, lipids at three months, HbA1c at three to six months and hormone levels where relevant; the topical half by photographs at baseline, three and six months and an annual skin-cancer check; procedures by photographs that separate each effect. One annual full review, with triggers — a new symptom, a new drug, an abnormal result — that reopen the plan sooner.
How many items should a complete plan have?
Six to ten, mostly generic: a few systemic drugs where the numbers warrant, sunscreen and tretinoin and a pigmentation agent if needed, a procedure or two if wanted, and the lifestyle prescriptions written down. A plan with twenty items and a peptide is not more complete — the additional items are the ones with the least evidence and the most interactions.
Keep reading
- How do I choose a medical-grade antiaging treatment plan?
The method for telling a plan from a menu.
- How to build an antiaging regimen using medical treatments?
The topical half, week by week.
- What are the most effective antiaging prescription treatments available?
The systemic and topical drugs ranked together.
- Free stack check
The medication review that joins the two halves.
More in Anti-aging pharma
- Rapamycin for longevity: what the human evidence actually shows
The only 48-week human trial (PEARL, n=129) missed its primary endpoint. What rapamycin has actually shown, the real risks, and who should never take it.
- What are the most effective antiaging prescription treatments available?
Anti-ageing prescription treatments ranked on randomised human evidence: tretinoin, botulinum toxin and fillers for visible ageing; GLP-1 agonists for metabolic ageing; statins and antihypertensives for the ageing that kills — and rapamycin, metformin, hormones and senolytics, which are prescribed for ageing without evidence for it.
- Which antiaging medicines deliver clinically proven wrinkle reduction results?
Medicines with clinically proven wrinkle reduction, ranked on randomised trials: botulinum toxin for dynamic lines, tretinoin and tazarotene for photoageing wrinkles, hyaluronic-acid fillers for folds, adapalene, then the over-the-counter retinol and peptides — and why sunscreen underwrites all of them.
- What antiaging pharmaceuticals work best for skin rejuvenation?
Anti-ageing pharmaceuticals for skin rejuvenation ranked on randomised evidence across texture, pigmentation, lines and volume: tretinoin, hydroquinone and tranexamic acid, botulinum toxin, fillers, azelaic acid, adapalene, oral isotretinoin (low-dose) — and the systemic drugs that do nothing for skin.
- Which doctor-prescribed antiaging drugs are safest long term?
Doctor-prescribed anti-ageing drugs ranked on long-term safety data: statins and antihypertensives (decades, millions), topical tretinoin, menopausal HRT in the window, GLP-1 agonists (years), metformin off-label, low-dose rapamycin, senolytics, testosterone 'optimisation' and growth hormone — with what is actually known about each over years.
- How do I choose a medical-grade antiaging treatment plan?
A ranked method for choosing a medical-grade anti-ageing treatment plan: measure first, treat what is measured, prefer on-label evidence, separate skin from systemic, demand monitoring, price the plan honestly — and the clinic-menu features that mean it is not medical-grade at all.